News
Novo Nordisk CEO Faces Investor Challenge Amidst Marketplace Turmoil
Novo Nordisk's new CEO, Maziar Mike Doustdar, is tasked with revitalizing the company's flagging sales and addressing investor concerns. His initial challenges include managing the downturn in Wegovy's sales amidst fierce competition in the obesity drug market,
Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...
Maziar Mike Doustdar spent more than three decades quietly climbing the ranks of Novo Nordisk A/S, from office clerk through ...
Danish pharmaceutical giant Novo Nordisk on Tuesday named its new CEO and cut its full-year sales and profit guidance.
Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales ...
It’s not unusual for a non-national to be CEO, executive director, or president of a company in a country. “C-level” positions and top management roles are often international. However, when the ...
Novo Nordisk's new CEO, Maziar Mike Doustdar, faces challenges in reviving waning sales and shares in the weight-loss drug ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback